Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Susanne M Rittig"'
Autor:
Jonas S. Heitmann, Claudia Tandler, Maddalena Marconato, Annika Nelde, Timorshah Habibzada, Susanne M. Rittig, Christian M. Tegeler, Yacine Maringer, Simon U. Jaeger, Monika Denk, Marion Richter, Melek T. Oezbek, Karl-Heinz Wiesmüller, Jens Bauer, Jonas Rieth, Marcel Wacker, Sarah M. Schroeder, Naomi Hoenisch Gravel, Jonas Scheid, Melanie Märklin, Annika Henrich, Boris Klimovich, Kim L. Clar, Martina Lutz, Samuel Holzmayer, Sebastian Hörber, Andreas Peter, Christoph Meisner, Imma Fischer, Markus W. Löffler, Caroline Anna Peuker, Stefan Habringer, Thorsten O. Goetze, Elke Jäger, Hans-Georg Rammensee, Helmut R. Salih, Juliane S. Walz
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract T-cell immunity is central for control of COVID-19, particularly in patients incapable of mounting antibody responses. CoVac-1 is a peptide-based T-cell activator composed of SARS-CoV-2 epitopes with documented favorable safety profile and e
Externí odkaz:
https://doaj.org/article/b32dbe5fcabf453983d2e107f672acc4
Autor:
Susanne M. Rittig, Martina S. Lutz, Kim L. Clar, Yanjun Zhou, Korbinian N. Kropp, André Koch, Andreas D. Hartkopf, Martina Hinterleitner, Lars Zender, Helmut R. Salih, Stefanie Maurer, Clemens Hinterleitner
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
In conventional T cells, OX40 has been identified as a major costimulating receptor augmenting survival and clonal expansion of effector and memory T cell populations. In regulatory T cells, (Treg) OX40 signaling suppresses cellular activity and diff
Externí odkaz:
https://doaj.org/article/5e3be70851314d40a577ae226ae4ff65
Autor:
Sarah Schnitte, Moritz Schmidt, Susanne M. Rittig, Stefanie Maurer, Vanessa Altdörfer, Alexander Rolf Fuchs, Daniela Dörfel, Martin Müller, Helmut R. Salih, Korbinian N. Kropp, Frank Grünebach
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 21, Iss 7, Pp 653-664 (2019)
Neoplasia (New York, N.Y.)
Neoplasia (New York, N.Y.)
The ubiquitin-proteasome system is elementary for cellular protein degradation and gained rising attention as a new target for cancer therapy due to promising clinical trials with bortezomib, the first-in class proteasome inhibitor meanwhile approved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf40dc61a5e2ce5126841209e64ad43f
https://doi.org/10.1016/j.neo.2019.03.001
https://doi.org/10.1016/j.neo.2019.03.001
Autor:
Susanne M. Rittig, Christian J. Lechner, Stefanie Maurer, Michael Gutknecht, Daniela Dörfel, Julian Geiger, Korbinian N. Kropp, Helmut R. Salih, Hans-Georg Kopp, Tanja Funk, Martin Müller, Simone Joas, Julia Salih, Frank Grünebach
Publikováno v:
Cancer Immunology, Immunotherapy. 67:775-783
In chronic myeloid leukemia (CML), the translocation t(9;22) results in the fusion protein BCR-ABL (breakpoint cluster region-abelson murine leukemia), a tyrosine kinase mediating oncogenic signaling which is successfully targeted by treatment with B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec1eee513e62e164445c06256e5a2ddc
https://doi.org/10.1007/s00262-018-2129-9
https://doi.org/10.1007/s00262-018-2129-9
Autor:
Alexander Steinle, Daniela Dörfel, Benedikt Strunz, Hans-Georg Kopp, Frank Grünebach, Korbinian N. Kropp, Moritz Schmidt, Kim L. Clar, Kathrin Rothfelder, Bastian J. Schmied, Susanne M. Rittig, Helmut R. Salih, Stefanie Maurer
Publikováno v:
Cancer immunology, immunotherapy : CII. 67(6)
The first therapeutic proteasome inhibitor bortezomib has clinical efficacy in mantle cell lymphoma (MCL) which resulted in its incorporation in treatment algorithms for this disease. Impairment of proteasomal function by bortezomib is mediated via i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4dc01339417cd8d8fa15997aae01dce
https://pubmed.ncbi.nlm.nih.gov/29556699
https://pubmed.ncbi.nlm.nih.gov/29556699
Autor:
Mark-Alexander Schwarzbich, Helmut R. Salih, Julia Salih, Frank Grünebach, Michael Gutknecht, Susanne M Rittig, Peter Brossart
Publikováno v:
Cancer Immunology, Immunotherapy. 61:193-202
Multiple approaches presently aim to combine targeted therapies using tyrosine kinase inhibitors with immunotherapy. Ex vivo-generated dendritic cells are frequently used in such strategies due to their unique ability to initiate primary T-cell immun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f99f2f90e0d52f8311146a03c22007e7
https://doi.org/10.1007/s00262-011-1096-1
https://doi.org/10.1007/s00262-011-1096-1
Autor:
Marius Horger, Lothar Kanz, Susanne M Rittig, Steve Pascolo, Wolfram Brugger, Tobias A W Holderried, Arnulf Stenzl, O. Maksimovic, Ingmar Hoerr, Annkristin Heine, Katrin J Weimer, Peter Brossart, Martin Müller, Hans-Georg Rammensee, Maik Haentschel
Publikováno v:
Oncoimmunology
Renal cell carcinoma (RCC) is an immunogenic tumor for which immunotherapeutic approaches could be associated with clinically relevant responses. It was recently shown, that induction of T-cell responses against multiple tumor-associated antigen (TAA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::486394a58694614550dff736bcca7471
http://europepmc.org/articles/PMC4910748
http://europepmc.org/articles/PMC4910748
Autor:
Simone, Kayser, Cristina, Boβ, Judith, Feucht, Kai-Erik, Witte, Alexander, Scheu, Hans-Jörg, Bülow, Stefanie, Joachim, Stefan, Stevanović, Michael, Schumm, Susanne M, Rittig, Peter, Lang, Martin, Röcken, Rupert, Handgretinger, Tobias, Feuchtinger
Publikováno v:
Oncoimmunology. 4(5)
Tumor-associated antigens such as NY-ESO-1 are expressed in a variety of solid tumors but absent in mature healthy tissues with the exception of germline cells. The immune system anti-cancer attack is mediated by cell lysis or induction of growth arr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f15f1092b9aab145c24d14c9a107cb28
https://pubmed.ncbi.nlm.nih.gov/26155389
https://pubmed.ncbi.nlm.nih.gov/26155389
Autor:
Sebastian-Jonas, Saur, Maik, Häntschel, Ferruh, Artunc, Susanne M, Rittig, Ulrike, Janssen, Lothar, Kanz, Karl, Jaschonek, Wichard, Vogel, Hans-Georg, Kopp
Publikováno v:
Deutsche medizinische Wochenschrift (1946). 138(16)
We report on the case of a young women presenting with macrohaematuria, petechiae and strong headaches.Laboratory showed a thrombotic microangiopathy with helmet cells, increased LDH levels (600 U/l), and thrombocytopenia (40,000/μl).Due to strong h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::41f8bf705f1edb2af0827d09b9ce2110
https://pubmed.ncbi.nlm.nih.gov/23608886
https://pubmed.ncbi.nlm.nih.gov/23608886
Autor:
Hans-Georg Rammensee, Susanne M Rittig, Stefan Stevanovic, Daniel J. Kowalewski, Oliver Kohlbacher, Simon Walz, Juliane S. Stickel, Linus Backert, Katja Weisel, Helmut R. Salih, Heiko Schuster, Lothar Kanz
Publikováno v:
Blood Cancer Journal
Recent studies suggest that multiple myeloma is an immunogenic disease, which might be effectively targeted by antigen-specific T-cell immunotherapy. As standard of care in myeloma includes proteasome inhibitor therapy, it is of great importance to c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94410bfebfa231b547a83672dbbef294
http://europepmc.org/articles/PMC4855252
http://europepmc.org/articles/PMC4855252